Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[5][7] It contains doravirine, lamivudine, and tenofovir disoproxil.[8][7] It is taken by mouth.[5]
| Combination of | |
|---|---|
| Doravirine | Non-nucleoside reverse transcriptase inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Delstrigo |
| Other names | MK-1439A |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618049 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[8][9][10]
References edit
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 8 July 2020. Retrieved 1 October 2020.
- ^ a b c "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
- ^ "Delstrigo EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
- ^ a b Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
- ^ a b "FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
- ^ "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.
- ^ "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
External links edit
- "doravirine lamuvidine tenofovir disoproxil fumarate". Canadian Agency for Drugs and Technologies in Health (CADTH).
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |